Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen

Calcified Tissue International

Volumn 90, Issue 4, 2012, Pages 263-271

  Kulak, Carolina A M ^a,b,c   Baz Hecht, Merav ^a   Nieves, Jeri ^a,b   Shen, Victor ^a   Lindsay, Robert ^a,b   Cosman, Felicia ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Estrogen; Estrogen agonist antagonist; Interleukin; PTH infusion; Renal calcium absorption

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; CONJUGATED ESTROGEN; INTERLEUKIN 6; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PHOSPHORUS; PLACEBO; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; BLOOD SAMPLING; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CATABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKELETON; URINALYSIS;

CALCIUM; COLLAGEN TYPE I; ESTROGENS; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDES; PROSPECTIVE STUDIES; RALOXIFENE; TAMOXIFEN;

EID: 84859912717     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9572-y     Document Type: Review

References (39)

1. F Albright PH Smith AM Richardson 1941 Postmenopausal osteoporosis JAMA 116 2465 2474 10.1001/jama.1941.02820220007002
2. JM Aitken DM Hart JB Anderson R Lindsay DA Smith CF Speirs 1973 Osteoporosis after oophorectomy for non-malignant disease Br Med J 1 325 328 10.1136/bmj.2.5862.325
3. R Lindsay DM Hart C Forrest C Baird 1980 Prevention of spinal osteoporosis in oophorectomised women Lancet 2 8205 1151 1154 6107766 10.1016/S0140-6736(80)92592-1 1:STN:280:DyaL3M%2FltFemtg%3D%3D (Pubitemid 11240800)
4. GL Anderson M Limacher AR Assaf T Bassford SA Beresford H Black, et al. 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 14 1701 1712 15082697 10.1001/jama.291.14.1775 1:CAS:528:DC%2BD2cXjt1WktLw%3D (Pubitemid 38489892)
5. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 321 333 12117397 10.1001/jama.288.3.321 1:CAS:528:DC%2BD38Xltlegs7k%3D (Pubitemid 34761611)
6. C Christiansen MS Christensen J Jensen P McNair C Hagen KE Stocklund, et al. 1980 Prevention of early post-menopausal bone mineral loss. Controlled 2-year study of 315 women [in Danish] Ugeskr Laeger 142 44 2896 2901 6255653 1:STN:280:DyaL3M%2FotVCnug%3D%3D (Pubitemid 11149738)
7. T Steiniche C Hasling P Charles EF Eriksen L Mosekilde F Melsen 1989 A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis Bone 10 5 313 320 2690898 10.1016/8756-3282(89)90126-9 1:STN:280:DyaK3c7gsFSruw%3D%3D (Pubitemid 20072023)
8. BL Riggs S Khosla LJ Melton 3rd 2002 Sex steroids and the construction and conservation of the adult skeleton Endocr Rev 23 3 279 302 12050121 10.1210/er.23.3.279 1:CAS:528:DC%2BD38XltlWjtrs%3D (Pubitemid 34651948)
9. PD Delmas P Hardy P Garnero M Dain 2000 Monitoring individual response to hormone replacement therapy with bone markers Bone 26 6 553 560 10831925 10.1016/S8756-3282(00)00271-4 1:CAS:528:DC%2BD3cXjsVGgs7o%3D (Pubitemid 30301646)
10. F Cosman V Shen F Xie M Seibel A Ratcliffe R Lindsay 1993 Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers Ann Intern Med 118 5 337 343 8430979 1:STN:280:DyaK3s7lvFSitA%3D%3D (Pubitemid 23070617)
11. US Masiukiewicz M Mitnick BI Gulanski KL Insogna 2002 Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women J Clin Endocrinol Metab 87 6 2892 2898 12050269 10.1210/jc.87.6.2892 1:CAS:528:DC%2BD38XkvFaqsrw%3D (Pubitemid 34655359)
12. S Srivastava G Toraldo MN Weitzmann S Cenci FP Ross R Pacifici 2001 Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappaB ligand (RANKL)-induced JNK activation J Biol Chem 276 12 8836 8840 11121427 10.1074/jbc.M010764200 1:CAS:528:DC%2BD3MXisVCnt7s%3D
13. P Vural C Akgul M Canbaz 2006 Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women Pharmacol Res 54 4 298 302 16879975 10.1016/j.phrs.2006.06.006 1:CAS:528:DC%2BD28XotlKjurs%3D (Pubitemid 44233334)
14. TC Spelsberg M Subramaniam BL Riggs S Khosla 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton Mol Endocrinol 13 6 819 828 10379881 10.1210/me.13.6.819 1:CAS:528: DyaK1MXjs1ynsr4%3D (Pubitemid 30645300)
15. J Pfeilschifter R Koditz M Pfohl H Schatz 2002 Changes in proinflammatory cytokine activity after menopause Endocr Rev 23 1 90 119 11844745 10.1210/er.23.1.90 1:CAS:528:DC%2BD38XitFOqu7c%3D (Pubitemid 34185307)
16. SL Teitelbaum 2000 Bone resorption by osteoclasts Science 289 5484 1504 1508 10968780 10.1126/science.289.5484.1504 1:CAS:528:DC%2BD3cXmt1KgsLk%3D
17. M Saika D Inoue S Kido T Matsumoto 2001 17Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha Endocrinology 142 6 2205 2212 11356664 10.1210/en.142.6.2205 1:CAS:528:DC%2BD3MXjvFGgur4%3D (Pubitemid 32473073)
18. F Cosman J Nieves J Horton V Shen R Lindsay 1994 Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women J Clin Endocrinol Metab 78 4 939 943 8157725 10.1210/jc.78.4.939 1:STN:280: DyaK2c3gvFertw%3D%3D (Pubitemid 24118092)
19. R Marcus ML Villa M Cheema C Cheema K Newhall L Holloway 1992 Effects of conjugated estrogen on the calcitriol response to parathyroid hormone in postmenopausal women J Clin Endocrinol Metab 74 2 413 418 1309837 10.1210/jc.74.2.413 1:CAS:528:DyaK38Xit1ynt78%3D
20. 2+ reabsorption in the connecting tubule Pflugers Arch 458 1 99 109 18989697 10.1007/s00424-008-0602-6 1:CAS:528:DC%2BD1MXktVGksLc%3D
21. 1 alpha-hydroxylase reserve in postmenopausal osteoporosis Calcif Tissue Int 42 2 77 86 3127028 10.1007/BF02556338 1:STN:280:DyaL1c7msVGrtw%3D%3D (Pubitemid 18050532)
22. BL Riggs LC Hartmann 2003 Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice N Engl J Med 348 7 618 629 12584371 10.1056/NEJMra022219 1:CAS:528:DC%2BD3sXhtVyqtLs%3D (Pubitemid 36210865)
23. F Cosman 2003 Selective estrogen-receptor modulators Clin Geriatr Med 19 2 371 379 12916292 10.1016/S0749-0690(02)00114-3 (Pubitemid 36514525)
24. KM Prestwood M Gunness DB Muchmore Y Lu M Wong LG Raisz 2000 A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women J Clin Endocrinol Metab 85 6 2197 2202 10852452 10.1210/jc.85.6.2197 1:CAS:528:DC%2BD3cXlsVequ7g%3D (Pubitemid 32269244)
25. A Cranney P Tugwell N Zytaruk V Robinson B Weaver J Adachi, et al. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis Endocr Rev 23 4 524 528 12202467 10.1210/er.2001-4002 1:CAS:528: DC%2BD38Xnt1Wiu74%3D (Pubitemid 34925646)
26. E Siris JD Adachi Y Lu T Fuerst GG Crans M Wong, et al. 2002 Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation Osteoporos Int 13 11 907 913 12415439 10.1007/s001980200125 1:CAS:528: DC%2BD38Xot12mur8%3D (Pubitemid 35364793)
27. A Rogers JA Clowes CA Pereda R Eastell 2007 Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies Bone 40 1 105 110 16934544 10.1016/j.bone.2006.07.011 1:CAS:528:DC%2BD28Xht12ktrrL (Pubitemid 44839336)
28. B Ozmen C Kirmaz K Aydin SO Kafesciler F Guclu Z Hekimsoy 2007 Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis Eur Cytokine Netw 18 3 148 153 17823083 1:CAS:528:DC%2BD2sXhtF2qtLbO (Pubitemid 47573424)
29. H Michael PL Harkonen L Kangas HK Vaananen TA Hentunen 2007 Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br J Pharmacol 151 3 384 395 17420779 10.1038/sj.bjp.0707232 1:CAS:528:DC%2BD2sXlslCqtbY%3D (Pubitemid 46842673)
30. C Mendez-Davila C Garcia-Moreno C Turbi C de la Piedra 2004 Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures J Endocrinol Invest 27 10 904 912 15762036 1:CAS:528:DC%2BD2MXhvFCku7Y%3D (Pubitemid 40124184)
31. F Cosman V Shen B Herrington R Lindsay 1991 Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay J Clin Endocrinol Metab 73 6 1345 1351 1955517 10.1210/jcem-73-6-1345 1:CAS:528:DyaK38XpvFOlsA%3D%3D (Pubitemid 121000714)
32. D Duncam 1955 Multiple range and multiple F tests Biometrics 11 1 42 10.2307/3001478
33. WR McKane S Khosla MF Burritt PC Kao DM Wilson SJ Ory, et al. 1995 Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause-a clinical research center study J Clin Endocrinol Metab 80 12 3458 3464 8530583 10.1210/jc.80.12.3458 1:CAS:528:DyaK2MXpvFSjt7Y%3D
34. US Masiukiewicz M Mitnick AB Grey KL Insogna 2000 Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro Endocrinology 141 7 2526 2531 10875254 10.1210/en.141.7.2526 1:CAS:528:DC%2BD3cXlt1Wmtbg%3D (Pubitemid 32269072)
35. S Kumru FM Yildiz A Godekmerdan S Kutlu B Yilmaz B Gurates 2008 Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial Arch Gynecol Obstet 277 6 489 493 18066566 10.1007/s00404-007-0521-3 1:CAS:528:DC%2BD1cXltFeqs7k%3D
36. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 6937 337 342 12748652 10.1038/nature01658 1:CAS:528:DC%2BD3sXjs1ynu7g%3D (Pubitemid 40852708)
37. D Fernandez-Garcia M Munoz-Torres P Mezquita-Raya M de la Higuera G Alonso R Reyes-Garcia, et al. 2008 Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis J Endocrinol Invest 31 5 416 421 18560259 1:CAS:528:DC%2BD1cXpslGrurY%3D (Pubitemid 352003235)
38. J Cheung YT Mak S Papaioannou BA Evans I Fogelman G Hampson 2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene J Endocrinol 177 3 423 433 12773123 10.1677/joe.0.1770423 1:CAS:528:DC%2BD3sXkslCgtbk%3D (Pubitemid 36722298)
39. C Joborn S Ljunghall K Larsson E Lindh T Naessén L Wide G Akerström J Rastad 1991 Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement Clin Endocrinol 34 5 335 339 10.1111/j.1365-2265.1991.tb00302.x 1:CAS:528: DyaK3MXlslGntr4%3D